



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

OCULUS INNOVATIVE SCIENCES COMPLETES INCORPORATION OF LEGAL ENTITY IN THE NETHERLANDS AND PREPARES FOR OPENING EUROPEAN MANUFACTURING FACILITY FOR MICROCYN60™ DISINFECTANT

Bas Philippens joins company as general manager of Oculus Innovative Sciences Netherlands B.V., taking overall responsibility for all European marketing, manufacturing and distribution activities for revolutionary disinfectant and antiseptic.

PETALUMA, CA-- (December 19, 2003)— In preparation for obtaining CE Mark approval for Microcyn60™, a revolutionary liquid disinfectant/antiseptic, Oculus Innovative Sciences (www.oculusis.com) of the United States announced the creation of a wholly owned European subsidiary, Oculus Innovative Sciences Netherlands B.V., in Maastricht, The Netherlands.

Bas Philippens, general manager for the new Oculus Dutch entity, will be responsible for creating, developing and managing the European organization. Philippens recently served as a senior project manager in the corporate strategic operations for Abbott Vascular Devices in the Netherlands, and worked previously at Jomed, where he focused on developing and implementing the operations strategy for global business. In addition, Bas previously held international management positions in operations and engineering at Medtronic Vascular.

To support the commercialization of Microcyn60 in Europe, Oculus's business plan includes opening a new manufacturing facility in the southeastern part of the Netherlands in 2004. This well-developed region, close to both the German and the Belgian border, is known for its promising infrastructure. Combined with the governmental focus on a high-tech, high-quality business environment, the Dutch facility will be responsible for supplying the European market with the Microcyn60 "disruptive" disinfectant and antiseptic technology.

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative technologies that globally re-define the disinfectant and antiseptic markets. Oculus has developed the revolutionary Microcyn disinfectant and antiseptic with broad applications in such diverse markets

as consumer, medical, dental, veterinarian, cosmetic, wound healing, food processing and anti-bio-terrorism. The company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V. Please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.